Credit Suisse Group Reiterates “€82.00” Price Target for Sanofi (SAN)

Sanofi (EPA:SAN) has been assigned a €82.00 ($95.35) price objective by Credit Suisse Group in a research note issued on Thursday. The firm presently has a “buy” rating on the stock. Credit Suisse Group’s price objective would suggest a potential upside of 23.92% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Jefferies Financial Group set a €78.00 ($90.70) price target on Sanofi and gave the stock a “neutral” rating in a research report on Thursday, August 16th. Goldman Sachs Group set a €74.00 ($86.05) price target on Sanofi and gave the stock a “neutral” rating in a research report on Wednesday. UBS Group set a €68.00 ($79.07) price target on Sanofi and gave the stock a “neutral” rating in a research report on Wednesday. Barclays set a €80.00 ($93.02) price target on Sanofi and gave the stock a “neutral” rating in a research report on Thursday. Finally, Deutsche Bank set a €87.00 ($101.16) price target on Sanofi and gave the stock a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of €80.89 ($94.06).

Shares of SAN stock traded down €0.06 ($0.07) during mid-day trading on Thursday, reaching €66.17 ($76.94). 6,890,000 shares of the company’s stock traded hands, compared to its average volume of 3,050,000. Sanofi has a 12 month low of €63.09 ($73.36) and a 12 month high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Marijuana Stocks Investing Considerations

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply